Alex R. Thurman, Senior Vice President and Chief Financial Officer at GLAUKOS Corp (NASDAQ:GKOS), recently engaged in transactions involving the company’s common stock. On July 9, 2026, Mr. Thurman acquired 10,000 shares of GLAUKOS common stock through the exercise of stock options at a price of $38.68 per share, totaling $386,800. On the same day, he sold 10,000 shares of common stock at a price of $155.00 per share, for a total of $1,550,000. Both transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which was adopted on December 15, 2025.
The options exercised by Mr. Thurman had a conversion price of $38.68 per share and were part of a grant that vests over four years, with 25% vesting on the first anniversary of the grant date and the remaining amount vesting in equal monthly installments over the following three years. These specific options were set to expire on October 6, 2026.
Following these transactions, Mr. Thurman directly holds 43,681 shares of GLAUKOS common stock. This total includes 5,230 restricted stock units that have not yet vested or been delivered to him.The timing of these transactions is notable as GLAUKOS shares are trading near their 52-week high of $156.60, with the stock currently at $152.72. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value, placing it among companies on the Most Overvalued list. For investors seeking deeper insights, a comprehensive Pro Research Report is available for GKOS, one of 1,400+ US equities covered with expert analysis and actionable intelligence.
In other recent news, Glaukos Corporation has been the focus of several analyst updates and clinical developments. William Blair reiterated its Outperform rating on Glaukos, following a proposed local coverage determination on its iDose product, with discussions having concluded recently. Piper Sandler also maintained an Overweight rating and a $165.00 price target after surveying U.S. eye specialists, who suggested potential regulatory impacts could pose a 25-30% headwind to future iDose volumes. In parallel, Glaukos announced the completion of patient enrollment in its Phase 2 study for GLK-321, a treatment for Demodex blepharitis using the iLution platform.
Needham raised its price target for Glaukos to $150 from $136, citing a positive outlook on corneal treatment, though it noted mixed feedback on conversion to approvals. Stifel reiterated a Buy rating with a $170.00 price target after a regulatory meeting about the iDose LCD device, where major medical societies expressed support for potential changes. These developments highlight ongoing interest and activity around Glaukos’s product pipeline and regulatory landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
